Adeyemi, Oladipupo published the artcileA pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats, Application In Synthesis of 21829-25-4, the main research area is ECG pharmacol agent radiotelemetry; Diltiazem; Electrocardiogram; Flecainide; Methods; Nifedipine; Quinidine; Rat; Telemetry; Translation; Verapamil.
The current study aimed to identify its utility in assessing ECG (ECG) PR and QRS interval changes. Male Han-Wistar rats (~250 g) were implanted with radio-telemetry devices for the recording of ECG and haemodynamic parameters. Animals (n = 4-8) were treated with single doses of calcium (nifedipine, diltiazem or verapamil; CCBs) or sodium channel blockers (quinidine or flecainide; SCBs) or their corresponding vehicles in an ascending dose design. Pharmacokinetic anal. of blood samples was performed to allow comparison of effects to published data in other species. Of the CCBs, only diltiazem (300 mg/kg) prolonged the PR interval (49 ± 2 vs. vehicle: 43 ± 1 ms), although this was not statistically significant (p = .11). QA interval decreased with nifedipine (30 ± 1 vs. 24 ± 0 ms) and diltiazem (34 ± 1 vs. 27 ± 1 ms) but increased with verapamil (30 ± 0 vs. 37 ± 1 ms) demonstrating pharmacol. activity of each agent. Both SCBs, caused statistically significant (p < .05) increases in both intervals - quinidine (100 mg/kg; PR: 50 ± 2 vs. 43 ± 1 ms; QRS: 22 ± 2 vs. 18 ± 1 ms) and flecainide (9 mg/kg; PR: 56 ± 1 vs. 46 ± 1 ms; QRS: 27 ± 1 vs. 21 ± 1 ms). At similar plasma concentrations to other species, the conscious telemetered rat demonstrates limited utility in assessing PR interval prolongation by CCBs, despite significant contractility effects being observed However, results with SCBs demonstrate a potential application for evaluating drug-induced QRS prolongation. Journal of Pharmacological and Toxicological Methods published new progress about Blood. 21829-25-4 belongs to class pyridine-derivatives, name is Dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, and the molecular formula is C17H18N2O6, Application In Synthesis of 21829-25-4.